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Reactivation of the Epstein-Barr virus (EBV)
after allogeneic stem cell transplantation
(allo-SCT) may evoke a protective cellular
immune response or may be complicated
by the development of EBV-lymphoprolifera-
tive disease (EBV-LPD). So far, very little is
known about the incidence, recurrence, and
sequelae of EBV reactivation following allo-
SCT. EBV reactivation was retrospectively
monitored in 85 EBV-seropositive recipients
of a T-cell–depleted (TCD) allo-SCT and 65
EBV-seropositive recipients of an unmanipu-
lated allo-SCT. Viral reactivation (more than
50 EBV genome equivalents [gEq]/mL) was
monitored frequently by quantitative real-
time plasma polymerase chain reaction until
day 180 after SCT. Probabilities of develop-
ing viral reactivation were high after both
unmanipulated and TCD-allogeneic SCT
(31% 6 6% versus 65% 6 7%, respectively).
A high CD341 cell number of the graft ap-
peared as a novel significant predictor
(P 5 .001) for EBV reactivation. Recurrent
reactivation was observed more frequently
in recipients of a TCD graft, and EBV-LPD
occurred only after TCD-SCT. High-risk sta-
tus, TCD, and use of antithymocyte globulin
were predictive for developing EBV-LPD.
Plasma EBV DNA quantitatively predicted
EBV-LPD. The positive and negative predic-
tive values of a viral load of 1000 gEq/mL
were, respectively, 39% and 100% after TCD.
Treatment-related mortality did not differ sig-
nificantly between TCD and non-TCD trans-
plants, but the incidence of chronic graft-
versus-host disease was significantly less
in TCD patients. It is concluded that EBV
reactivation occurs frequently after TCD and
unmanipulated allo-SCT, especially in recipi-
ents of grafts with high CD341 cell counts.
EBV-LPD, however, occurred only after TCD,
and EBV load quantitatively predicted EBV-
LPD in recipients of a TCD graft. (Blood.
2001;98:972-978)
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Introduction
Epstein-Barr virus–associated lymphoproliferative disease (EBV-
LPD) is a serious complication of allogeneic stem cell transplanta-
tion (allo-SCT) and solid-organ transplantation.1-3 Although the
incidence of EBV-LPD is generally less than 2% after allo-SCT, it
may increase to 20% in patients with established risk factors, such
as unrelated donor SCT, the use of T-cell–depleted (TCD) allo-
grafts, use of antithymocyte globulin (ATG), and immunosuppres-
sion for prevention and treatment of graft-versus-host disease
(GVHD).4-8 EBV-LPD is associated with a poor prognosis despite
the use of anti–B-lymphocyte monoclonal antibody therapy,9-12
donor lymphocyte infusion (DLI),13 and infusion of EBV-specific
cytotoxic T cells.14,15 Therefore, early diagnosis and preventive
measures, such as B-cell depletion of the donor graft,4,7,16 and
pre-emptive therapy may be clinically useful.17-24
We developed a real-time polymerase chain reaction (PCR) assay for
the quantitative detection of EBV-DNA in plasma.25 The assay accu-
rately monitors viral load in plasma from patients with infectious
mononucleosis and immunocompromised patients at risk of EBV-LPD
or with established EBV-LPD.25,26 In contrast to cytomegalovirus
(CMV) antigenemia after allo-SCT and the risk of developing CMV
disease, little is known about reactivation of EBV during the first 3 to 6
months after allo-SCT and the predictive value of EBV reactivation for
subsequent EBV-LPD.Although several studies have shown an associa-
tion between viral load and a diagnosis of EBV-LPD,27-43 no study has
longitudinally followed a larger cohort of allo-SCT recipients with
multiple risk factors. We set out to monitor EBV reactivation by
real-time PCR at regular intervals after allo-SCT. Incidences, risk
factors, and sequelae of EBV reactivation were compared between
patients receiving a TCD-SCT and patients having transplantation with
an unmanipulated stem cell graft. We show that subclinical EBV
reactivation is a very frequent event after allo-SCT and that quantifica-
tion of EBV-DNA appears useful to identify patients at risk of
progression to overt EBV-LPD.
Patients and methods
Patients
The study population consisted of 152 consecutive patients treated at 4
transplant centers, who received stem cell transplants between March 1996
and June 1999. Patients underwent allografting at the department of
hematology of the university hospitals of Utrecht (TCD-SCT) or Rotterdam
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(TCD-SCT), The Netherlands; Essen (non–TCD-SCT), Germany; or Genoa
(non–TCD-SCT), Italy. Transplant protocols were approved by local
institutional review boards, and all patients provided informed consent.
Patient characteristics are presented in Table 1. Eighty-five patients
received a TCD-SCT and 67 patients received a non–TCD-SCT. Median
age was 41 years (range, 17-55 years) in the TCD group and 31 years
(range, 17-56 years) in the non-TCD group (P , .01). Standard-risk
patients had a diagnosis of acute lymphoblastic leukemia (ALL) in first
complete remission (CR1), acute myeloid leukemia (AML) in CR1, chronic
myeloid leukemia (CML) in first chronic phase, and untreated (very) severe
aplastic anemia (SAA). All other diagnoses were considered high risk. The
non-TCD group included more patients with CML and fewer patients with
lymphoma, multiple myeloma, or high-risk disease (P 5 .001). Unrelated
donor grafts were used more frequently in the non-TCD group (P 5 .001).
The use of ATG added to the conditioning regimen for prevention of
rejection was confined to patients having transplantation with TCD grafts
from unrelated donors.
Transplantation
The conditioning regimen preceding a TCD-SCT consisted of cyclophospha-
mide (120 mg/kg) and total-body irradiation (TBI) (12 Gy in 2 fractions).
Rabbit ATG (Imtix Sangstat, Amstelveen, The Netherlands) was given for
prevention of rejection before SCT in recipients of a TCD unrelated donor
graft. If patients had previously been treated with locoregional irradiation,
the conditioning regimen consisted of oral busulfan (4 mg/kg on each of 4
successive days) and cyclophosphamide (120 mg/kg). The conditioning
regimen in case of an unmanipulated SCT consisted of cyclophosphamide
(120 mg/kg) and TBI (10 Gy in 4 or 3 fractions).
Partial T-cell depletion was performed using sheep erythrocyte rosetting
(n 5 53) or CD34 selection (Cellpro, Wezembeek, Belgium) (n 5 32).
Median T-cell numbers differed more than 2 logs between TCD and
unmanipulated grafts (2.0 3 105/kg versus 510 3 105/kg), but numbers of
granulocyte-macrophage colony-forming units (CFU-GMs) and CD341
mononuclear cells (MNCs) did not differ significantly between the groups
of patients. Peripheral blood–derived stem cells were used relatively more
often than bone marrow–derived stem cells in patients receiving a TCD
graft as compared with patients receiving an unmanipulated graft (P , .01).
Graft-versus-host (GVH) prophylaxis was cyclosporin A (3 mg/kg) from
day 23 until day 1100 after TCD-SCT, and the combination of methotrex-
ate (15 mg/m2 on day 1; 10 mg/m2 on days 3, 6, and 11) and cyclosporin A
was used in recipients of an unmanipulated SCT.
All patients received ciprofloxacin and fluconazole for prevention of
infection during neutropenia, and cotrimoxazole was given after neutrophil
recovery until days 180 to 360 after SCT. Patients having transplantation in
Utrecht (TCD-SCT) and Genoa (non–TCD-SCT) received long-term
acyclovir prophylaxis from day 0 until day 360. Erythrocyte and platelet
products for transfusion were filtered to remove leukocytes and subse-
quently irradiated (25 Gy). Patients were hospitalized in reverse isolation in
rooms with high-efficiency particulate-filtered air. All patients received
food with a low microbial count until discharge, and parenteral alimentation
was given in case of severe mucositis.
Real-time Taqman assay
Taqman PCR primers were selected from the EBV-DNA genome encoding
for the nonglycosylated membrane protein BNRF1-p143 and generated a
DNA product of 74 base pairs, as described before.25 A known EBV-DNA
copy number based on a reference standard quantified by electron
microscopy (ABI Advanced Biotechnologies, Columbia, MA) was used for
standardization. Serial dilutions ranging from 10 to 107 EBV-DNA genome
equivalents per milliliter (gEq/mL) were made to characterize linearity,
precision, specificity, and sensitivity. The Taqman assay appeared to detect
viral DNA in plasma over a linear span between 50 and 107 gEq/mL, with
an average coefficient of variation of 1.56% (range, 0.7% to 7.0%). Test
results below 50 gEq/mL were considered negative. No viral DNA was
detected in plasma of healthy EBV-seropositive individuals.25 EBV reacti-
vation was defined as a plasma EBV-DNA level exceeding 50 gEq/mL.
Recurrent reactivation was defined by a positive PCR (more than 50
gEq/mL) after (at least) 2 consecutive negative PCR results following a
preceding episode of reactivation. Viral load was monitored in blood
samples drawn at 2-week intervals starting at SCT until day 180 after SCT.
EBV-LPD diagnosis
A diagnosis of EBV-LPD was preferably based on lymph node histology or
cytology and was classified according to the criteria of Knowles et al.44
Immunohistology included antibody staining with CD19-specific (Becton
Dickinson, San Jose, CA), CD20-specific (Dako, Glostrup, Denmark), and
EBV latent membrane protein-1–specific (Dako) monoclonal antibodies.
Furthermore, clonality was assessed using immunohistochemical staining
with monoclonal antibodies to kappa and lambda light chains (Dako). In
situ hybridization was performed to detect EBV-encoded small RNA
molecules (EBV-EBER) using an EBV-EBER probe (Dako) and PCR for




SCT (n 5 85)
Allogeneic non-T-cell-
depleted SCT (n 5 67) P
Sex male/female (n) 48/37 50/17 .02
Age, y (median, range) 41 (17-55) 31 (17-56) , .01
Diagnosis (n)
AML CR1 11 3
AML . CR1 8 8
ALL CR1 5 6
ALL . CR1 7 2
ALL CR1 Ph1 5 —
MDS 3 1
CML CP1 8 28
CML . CP1 5 16
SAA 5 —
MM 15 1
M. Hodgkin 2 —
NHL 10 2
CLL 1 —
Risk status: SR/HR (n) 25/60 37/30 .001
Donor type (n)









MNC 3 108/kg 0.13 (0.01-9.32) 3.43 (0.13-14.0)
CD3 3 105/kg 2.0 (1.0-7.5) 510 (7.4-2195) , .001
CFU-GM 3 104/kg 16.7 (1.9-85.9) 14.1 (4.0-132) .6
CD34 3 106/kg 1.25 (0.06-6.43) 2.2 (0.04-14.1) .7
EBV serology (n)
D-R- — 2 .2
D1R2/D1R1/D2R1 85 65
Stem cell source (n)
BM 66 63 , .01
PB 19 4
AML1 CR1 or . CR1 indicates acute myeloid leukemia in first or subsequent
complete remission; ALL CR1 or . CR1, acute lymphoblastoic leukemia in first or
subsequent CR; ALL CR1 Ph1, ALL CR1 Philadelphia chromosome-positive; MDS,
myelodysplastic syndrome; CML CP1 or . CP1, chronic myeloid leukemia in first or
subsequent chronic phase; SAA, severe aplastic anemia; MM, multiple myeloma; NHL,
non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; SR, standard risk; HR, high
risk; Sib, HLA-identical family donor; MUD, matched unrelated donor; Cy, cyclophospha-
mide; TBI, total-body irradiation; Bu, busulfan; ATG, antithymocyte globulin; MNC, mono-
nuclear cells; CFU-GM, granulocyte-macrophage colony-forming unit; D1/2, Epstein-Barr
virus (EBV)-seropositive/seronegative donor; R1/2, EBV-seropositive/seronegative recipi-
ent; BM, bone marrow; PB, peripheral blood.
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detection of EBV-DNA encoding for the BamHI fragment. EBV-LPD
staging included physical examination, whole-body computed tomography
(CT) scanning, and flow cytometric detection of monoclonal B lympho-
cytes in blood, bone marrow, and, if indicated, cerebrospinal fluid.
End points and statistical analysis
The data were analyzed as of January 2000. Patient characteristics of
non-TCD patients and TCD patients were compared using Fisher exact test
or Pearson chi-square test, whichever was appropriate, in case of discrete
variables, or the Wilcoxon rank-sum test in case of continuous variables.
End points of the study included time to EBV reactivation, EBV-LPD, acute
GVHD grades II to IV, chronic GVHD, and treatment-related mortality
(TRM). Time to first EBV reactivation was determined from the date of
transplantation until day 180, and patients were censored at the date of last
serum sample if this sample had been taken before day 180. Time to
EBV-LPD was measured from SCT until EBV-LPD. Patients who died
without EBV-LPD were censored at the date of death. Patients still alive at
the date of analysis were censored at the last follow-up date. Two
EBV-seronegative donor-recipient pairs were excluded from the analysis of
EBV reactivation and EBV-LPD. GVHD was diagnosed and graded
according to consensus criteria.45 Chronic GVHD was evaluated among
patients who survived at least 100 days after transplantation. TRM was
defined according to standard criteria.46 Time to EBV reactivation, EBV-
LPD, acute and chronic GVHD, and TRM were estimated by the
Kaplan-Meier method, and Kaplan-Meier curves were generated to illus-
trate differences between subgroups of patients.47 The following variables
were included in the analysis of prognostic factors: sex, male patient and
female donor, age, risk status, donor (sibling versus matched unrelated
donor), source of stem cells (bone marrow versus peripheral blood), type of
transplant (non-TCD versus TCD without ATG versus TCD with ATG), and
graft characteristics (number of MNCs, number of CD341 cells, number of
CD31 and CFU-GMs infused). Univariate survival analysis was performed
using the log-rank test and Cox regression to see whether there was a
difference between subgroups.48,49 The variables that appeared significant
in the univariate analysis were also included in a multivariate Cox
regression. Moreover, Cox regression was performed using EBV reactiva-
tion within day 180 as a time-dependent covariate to assess whether EBV
reactivation predicted EBV-LPD and TRM. All reported P values are
2-sided, and a significance level of a 5 .05 was used.
Results
EBV reactivation
The probability of developing EBV reactivation was greater after
TCD-allogeneic SCT than after non–TCD-SCT (Figure 1, Table 2).
That difference, however, could be largely attributed to the use of
ATG in conjunction with TCD (Figure 1, Table 3). Probabilities of
viral reactivation were not different between recipients of a
non–TCD-SCT and recipients of a TCD-SCT without concomitant
ATG. Median time to first reactivation was 58 days (range, 5-180
days) in the TCD group and 63 days (range, 2-107 days) in the
non-TCD group (not significant). Plasma EBV-DNA levels mea-
sured at the peak of the first reactivation did not differ between the
groups. Recurrent reactivation was significantly more frequent
after TCD (Table 2): 14 of 85 patients (16%) experienced multiple
episodes of EBV reactivation after TCD-SCT, including 8 patients
with 2 episodes, 5 patients with 3 episodes, and 1 patient showing 4
distinct periods of reactivation. This is exemplified for a recipient
of a TCD donor graft who experienced 3 episodes of EBV
reactivation without developing EBV-LPD (Figure 2). In contrast,
only 2 of 65 patients (3%) receiving non-TCD grafts had a second
period of reactivation. ATG appeared not to be associated with
recurrent reactivation, as only 2 of 14 patients with recurrent
reactivation after TCD also received ATG as part of the condition-
ing regimen. Several risk factors predicted first reactivation in
univariate analysis (Table 3), including TCD (P 5 .02), use of ATG
in the conditioning regimen (P , .001), transplantation of an
unrelated donor graft (P 5 .02), and a high CD341 cell number of
the graft (P 5 .001) (Figure 3). Following multivariate analysis,
only the use of ATG and a high CD341 cell count (. 1.35 3 106/
kg) remained independently associated with EBV reactivation
(Table 3). Numbers of CD341 and CD31 cells were not associated
with each other.
EBV-LPD
EBV-LPD was observed only after TCD-SCT (Table 2, Figure 4).
Five patients developed EBV-LPD after HLA-identical sibling
SCT and 5 after unrelated donor SCT (Table 4). Five of these
patients had received ATG before unrelated donor SCT, and 9 of
them had been treated for high-risk disease. All EBV-LPD donor-
recipient pairs were EBV seropositive. One donor had negative
EBV serology before transplantation. Median time from first
reactivation to EBV-LPD was 22 days (range, 13-120 days) (Table
2). Median EBV-DNA level at EBV-LPD diagnosis was 110 000
Figure 1. Incidence of EBV reactivation. Incidence of EBV reactivation after
TCD-allogeneic SCT with ATG (n 5 24), TCD-SCT without ATG (n 5 61), and
non–TCD-SCT (n 5 65). Only TCD combined with ATG significantly increased the
risk of EBV reactivation (P , .001).






No. of patients with EBV reactivation (%) 46 (54) 18 (28)
Time (d) to first EBV reactivation (median, range) 58 (5-180) 63 (2-107)
Maximum viral load (gEq/mL) of first EBV reactivation (median, range) 535 (50-3 200 000) 808 (55-540 000)
No. of patients (%) with recurrent EBV reactivation 14 (16) 2 (3)
No. of patients (%) with EBV-LPD 10 (12) —
Time (d) from SCT to EBV-LPD (median, range) 87 (50-168) —
Time (d) from first EBV reactivation to EBV-LPD (median, range) 22 (13-120) —
EBV-LPD viral load (gEq/mL, median, range) 110 000 (1800-790 000) —
gEq/mL indicates genome equivalents of EBV DNA/mL. Other abbreviations are explained in Table 1.
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gEq/mL (range, 1800-790 000 gEq/mL). Histologic proof of a
diagnosis of EBV-LPD and classification according to the criteria
of Knowles et al44 were obtained in 8 patients. Patient 8 (Table 4),
who received an HLA-identical sibling SCT for multiple myeloma,
was diagnosed with EBV-LPD by the presence of monoclonal B
cells in his cerebrospinal fluid and an elevated plasma EBV-DNA
level. Patient 9, who received an unrelated donor SCT because of
SAA, was diagnosed with EBV-LPD because of massive lymphad-
enopathy on CT scanning and a highly elevated plasma EBV-DNA
level. Six patients received anti–B-cell monoclonal antibody
therapy (rituximab), 5 patients received DLI, and immune suppres-
sion was discontinued in 8 patients (Table 4). Five patients obtained
a complete remission and 5 other patients died of progressive
EBV-LPD. Two responding patients are currently alive with a
follow-up of 620 and 351 days. Three responding patients devel-
oped severe GVHD, 2 following DLI, and died of GVHD-related
complications. Use of ATG, application of TCD, and high-risk
status of underlying disease significantly predicted EBV-LPD in
univariate analysis. Multivariate analysis was not performed be-
cause the latter 3 variables appeared strongly associated and the
small number of events did not allow a reliable multivari-
ate analysis.
Several risk factors occurring after SCT were evaluated for a
possible association with EBV-LPD by time-dependent analysis. A
lower lymphocyte count at first EBV reactivation appeared not
predictive for developing EBV-LPD. In contrast, EBV load signifi-
cantly predicted EBV-LPD in a quantitative manner. A stepwise
increase of EBV-DNA by 1 log (Table 5) yielded a hazard ratio
(HR) of 2.9 (95% confidence interval [CI], 1.7-4.8) for those
patients receiving a TCD graft (P , .001). Numbers of patients
with a TCD-SCT with plasma levels of EBV DNA exceeding a
certain threshold value and the corresponding positive and negative
predictive values for EBV-LPD for that subset of patients are
shown in Table 5. Although the positive predictive value was 24%
for patients with a copy number of 100 gEq/mL or higher, it rose to
100% at the level of 500 000 gEq/mL. However, only one patient
with EBV-LPD reached that high number, and consequently the
negative predictive value was 89%.
Graft-versus-host disease
The actuarial probability of acute GVHD grade II to IV at day 100
was 57% 6 4% for the whole group and was not significantly
different for patients receiving a TCD graft as compared with
patients receiving unmanipulated allo-SCT. An unrelated donor
graft and a high CD341 cell count of the graft (independent of the
number of CD31 T cells in the graft) were the only significant risk
factors for developing acute GVHD following multivariate analy-
sis. EBV reactivation was not associated with acute GVHD.
Actuarial probabilities of chronic limited and extensive GVHD at
12 months after SCT were significantly higher for non-TCD
patients (83% 6 5%) than for TCD patients (38% 6 6%)
(P , .001).
Treatment-related mortality
The actuarial probability of TRM was 29% 6 4% at 1 year for all
patients and did not differ between TCD and unmanipulated
allo-SCT. Higher age and a higher CD341 cell count (. 1.35 3 106/
kg) of the graft predicted higher TRM in multivariate analysis.
Following time-dependent analysis, EBV reactivation (HR 1.9;
95% CI, 1.0-3.3; P 5 .04) and acute GVHD grade II to IV (HR 1.8;
Figure 2. Monitoring EBV load after matched unrelated SCT. A 16-year-old
EBV-seropositive male with a Philadelphia chromosome–positive (Ph1) ALL in first
complete remission received a TCD matched unrelated donor graft from an
EBV-seropositive donor. Multiple EBV reactivations were observed; however, no
EBV-LPD ensued. Frequent examination of bone marrow for the presence of
monoclonal B cells and whole-body CT to detect lymphadenopathy were negative at
various time points (*). At day 211, DLI (1.0 3 105 CD31 T cells/kg) was administered
because of molecular relapse of his Ph1 ALL. Currently, the patient is free of disease
and well at day 800 after SCT. CyA indicates cyclosporin A.
Figure 3. Incidence of EBV reactivation by number of CD341 cells in the graft.
The median number of CD341 cells in the graft was 1.35 3 106/kg. Patients with
grafts containing more than 1.35 3 106/kg were at higher risk (P 5 .001) of EBV
reactivation.
Figure 4. Incidence of EBV-LPD. Incidence of EBV-LPD (n 5 10) after TCD-
allogeneic SCT combined with ATG (n 5 24), TCD-SCT without ATG (n 5 61), and
non–TCD-SCT (n 5 65).
Table 3. Univariate and multivariate Cox regression analysis of risk factors
for Epstein-Barr virus reactivation
Risk factor
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
T-cell depletion, no ATG 1.5 0.8-2.7 .02 1.5 0.8-2.9 .3
T-cell depletion, ATG 3.5 1.8-6.9 , .001 3.4 1.6-7.1 .001
High-risk status 1.6 1.0-2.8 .07 1.4 0.8-2.6 .2
Unrelated donor 1.8 1.1-2.9 .02 0.9 0.3-2.9 .8
CD341 cell count of the graft
(. 1.35 3 106/kg) 2.4 1.4-4.1 .001 2.6 1.5-4.6 .001
HR indicates hazard ratio; CI, confidence interval; ATG, antithymocyte globulin.
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95% CI, 1.0-3.3; P 5 .05) were associated with higher TRM. In
addition, a higher lymphocyte count (. 0.6 3 109/L) at the time of
first EBV reactivation significantly predicted less TRM (HR 0.3;
95% CI, 0.1-0.8; P 5 .02).
Discussion
This study demonstrates that EBV reactivation is a very frequent
event after both TCD and unmanipulated allo-SCT. In particular,
recipients of stem cell grafts with high numbers of CD341 MNCs
appeared to be at risk for EBV reactivation. However, patients
receiving a TCD-SCT were at significantly higher risk for recurrent
reactivation, and only these patients developed EBV-LPD. The
development of impending EBV-LPD in these patients could be
predicted quantitatively by monitoring viral load in plasma at
regular intervals during the first 6 months after SCT.
EBV reactivation was observed frequently after TCD-SCT and
after unmanipulated allo-SCT as well. The high incidence of first
EBV reactivation after TCD-SCT could be largely attributed to the
use of ATG and, as a result, TCD per se did not appear to be an
independent risk factor for early EBV reactivation. However,
patients receiving a TCD-SCT showed more recurrence of reactiva-
tion, and EBV-LPD was observed only after TCD. Because the
conditioning regimen has eradicated autologous EBV-specific
immunity after both TCD and unmanipulated SCT, early EBV
reactivation may occur after both modes of allo-SCT.50,51 However,
the significantly higher risks for recurrent EBV reactivation and
EBV-LPD in TCD-SCT as compared with unmanipulated SCT may
be explained by the impaired capacity of patients receiving TCD
grafts to mount an effective immune response to the reactivating
virus. The strongly reduced numbers of EBV-specific memory T
cells in TCD as compared with unmanipulated grafts may play a
major role in this respect.52,53
Apart from the use of ATG as part of the conditioning regimen,
we identified the number of CD341 cells in the graft as a novel
independent risk factor for developing EBV reactivation (Table 3,
Figure 3), and also for acute GVHD and TRM. Przepiorka et al54
recently reported that recipients of peripheral blood stem cell grafts
with high CD341 cell counts were at higher risk for acute GVHD,
an effect that appeared independent of the number of CD31 T cells.
They suggested that GVHD at high CD341 cell doses may be
exacerbated by cytokines released by the markedly expanding
myeloid population at the time of engraftment. This explanation is
supported by high levels of proinflammatory cytokines in patients
with severe GVHD.55-57 In the present study, acute GVHD signifi-
cantly predicted TRM in a time-dependent analysis. Therefore, the
association of CD341 cell dose and TRM might be explained by an
increased incidence of GVHD. The association of CD341 cell dose
and EBV reactivation, however, is less likely to be explained by
more GVHD, because EBV reactivation preceded the onset of
acute GVHD in a significant number of patients. Alternative
explanations may include infusion of a higher number of EBV-
infected B cells together with larger stem cell grafts, or stimulation
of B-cell proliferation by cytokines produced by the higher number
of rapidly maturing myeloid progenitors. The latter explanation is
supported by a number of preclinical as well as clinical studies
showing that proinflammatory cytokines, such as interleukin-1
(IL-1), tumor necrosis factor-a and -b, and IL-6, may very
effectively stimulate the growth of EBV-infected B cells.58 In
particular, IL-6 may play an important role as a growth factor,
promoting the progression toward overt EBV-LPD.59-62 Apart from
monocyte-macrophages and endothelial cells as an established
source of proinflammatory cytokines, the rapidly proliferating
myeloid population of grafts containing high CD341 cell
doses may add to cytokine release and thus contribute to viral
reactivation.
A number of studies have demonstrated a correlation between
high levels of viral load and a diagnosis of EBV-LPD after both
SCT and solid-organ transplantation.26-43 No study, however, has
longitudinally followed allo-SCT recipients with multiple risk
factors from day 0 until day 180 and reported positive and negative
predictive values. Lucas et al41 evaluated the predictive value of
quantitative PCR using DNA extracted from peripheral blood










CD20 DLI Response Survival, d COD
1 Sib III Mono 1 800 1 2 1 PD Dead EBV-LPD
2 MUD II Poly 92 000 1 1 1 CR Dead GVHD
3 MUD II Poly 6 500 1 1 2 CR Alive, 6201 —
4 Sib III Mono 790 000 1 1 1 PD Dead EBV-LPD
5 Sib III Mono 128 000 1 1 2 CR Alive, 3511 —
6 Sib II Mono 74 000 1 1 2 CR Dead GVHD
7 MUD III Mono 133 000 1 1 1 PD Dead EBV-LPD
8 Sib ND Mono 7 900 1 2 2 PD Dead EBV-LPD
9 MUD ND ND 310 000 2 2 1 CR Dead GVHD
10 MUD III Mono 206 000 2 2 2 PD Dead EBV-LPD
gEq/mL indicates genome equivalents of EBV DNA/mL; SI, stop immunosuppression; anti-CD20, monoclonal anti-B-cell therapy; DLI, donor lymphocyte infusion; COD,
cause of death; Sib, HLA-identical family donor; Mono, monoclonal disease; PD, progressive disease; MUD, matched unrelated donor; Poly, polyclonal disease; CR, complete
remission; GVHD, graft-versus-host disease; ND, not determined.
*I indicates plasma cell hyperplasia; II, polymorphic hyperplasia; III, non-Hodgkin lymphoma (criteria according to Knowles et al44).
Table 5. Incidence of Epstein-Barr virus-lymphoproliferative disease by viral









Positive (%) Negative (%)
100 41 10 24 100
1 000 26 10 39 100
10 000 14 7 50 96
100 000 7 5 71 94
500 000 1 1 100 89
gEq/mL indicates genome equivalents of EBV DNA/mL. Other abbreviations are
explained in Table 1.
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MNCs in a cohort of 195 patients receiving solid-organ transplanta-
tion. Although the negative predictive value appeared very high
(100%), the positive predictive value was 38%. Our results
observed in recipients of an allo-SCT are in line with these
findings. Considering both TCD and non-TCD transplants, the
negative and positive predictive values of a copy number of 1000
gEq/mL were, respectively, 100% and 28%. Higher predictive
values were obtained when the analysis was restricted to patients
receiving a TCD-SCT. The positive predictive values of a high
EBV-DNA level of more than 1000 gEq/mL and more than 10 000
gEq/mL for patients receiving TCD-SCT were 39% and 50%,
respectively (Table 5).
Although highly significant, these predictive values also indi-
cate that most patients (even recipients of TCD grafts) were able to
mount an effective immune response and clear their viral reactiva-
tion. Monitoring of the reconstitution of HLA-specific T lympho-
cytes may add to the predictive value of viral load quantification.
For this purpose, rapid assays are now available, such as the
enumeration of EBV-specific T lymphocytes by tetramer binding or
the induction of intracellular interferon-g in T cells after specific
stimulation.63 The accurate prediction of impending EBV-LPD in
patients at risk is important because pre-emptive therapy might be
more effective than therapy of established EBV-LPD. Despite the
application of new treatment modalities such as DLI and anti–B-
cell immunotherapy, the mortality of patients with established
EBV-LPD is still high. Ten patients developed EBV-LPD in the
present study: 5 died of progressive EBV-LPD and 3 patients died
of GVHD following DLI, resulting in 80% (8 of 10) mortality.
Pre-emptive infusion of EBV-specific cytotoxic T cells has been
shown to reduce viral load and may prevent the evolution toward
EBV-LPD.20 However, the preparation and use of such EBV-
specific T cells is expensive and difficult to implement on a wide
scale. B-cell depletion of the donor graft has been shown to
effectively reduce the incidence of EBV-LPD.7,16 Therefore, anti–B-
cell immunotherapy aimed at in vivo B-cell depletion after SCT in
patients at high risk of EBV-LPD might be a promising new means
of pre-emptive therapy. A prospective phase II study with that
specific aim is currently being performed.64 Because the depletion
of B cells may further impair the immune status of these patients,
one may argue to restrict pre-emptive therapy to those patients at
highest risk. A threshold of 1000 gEq/mL, as observed in our
patient population, may thereby serve as a critical level of viral load
to start pre-emptive therapy. Thus, pre-emptive therapy may be
administered selectively to high-risk patients to prevent EBV-LPD
and to avoid treatment of patients who have recovered their
EBV-specific immunity to protective levels. The frequent monitor-
ing of EBV load after allo-SCT may therefore be considered for
patients with a high-risk profile for EBV-LPD and may preferably
be combined with close monitoring of the reconstitution of
EBV-specific T lymphocytes.
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